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Background: Cytokines mediate a variety of effector cell functions, including
cellular proliferation, differentiation, and modulation of the immune response.
Many cytokines activate receptor-associated Janus kinases (JAKs) that promote
tyrosine phosphorylation of signal transducers and activators of transcription
(STAT) factors. Although JAK activation has been correlated with
phosphorylation, the role of this tyrosine phosphorylation in the regulation of
JAK1 and JAK3 remains unclear. Furthermore, the relative roles of JAK1 and
JAK3 in the activation of STAT5 by interleukin-2 (IL-2) remain poorly
understood.
Results: We targeted two conserved tyrosine residues within the activation
loop of the JAK1 and JAK3 kinase domains for substitution with phenylalanines.
In an overexpression system, the catalytic function of JAK1 strictly required the
presence of the first of these tyrosines, Y1033. In contrast, JAK3 retained
catalytic activity when either or both of these activation-loop tyrosines were
mutated. Analysis of JAK1/3 chimeras demonstrated that JAK activity was also
controlled by intramolecular interactions involving the amino-terminal domain of
the JAK as well as by the inherent signaling properties of the kinase domain.
Finally, we have reconstituted IL-2-dependent STAT5 induction in a cell line that
lacks detectable expression of JAK1 and JAK3. Catalytically active versions of
both JAK1 and JAK3 must be present for effective induction of STAT5.
Conclusions: JAK1 and JAK3 are differentially regulated by specific tyrosines
within their respective activation loops. Additionally, the amino-terminal domain
of JAK3 appears to contain regulatory sequences that modify the function of the
kinase domain. Finally, both JAK1 and JAK3 must retain catalytic function for 
IL-2-induced STAT5 activation.
Background
One of the most extensively studied cytokines is inter-
leukin-2 (IL-2), which has pleiotropic biological effects,
including stimulation of the growth and differentiation of
T and B lymphocytes and activation of natural killer cells
(for a review, see [1]). IL-2 acts by binding to the multi-
meric IL-2 receptor (IL-2R), which is composed of three
transmembrane proteins. Whereas the primary role of the
IL-2Rα chain is to regulate the affinity of the receptor
complex for its ligand [2–4], intracellular signaling results
from the heterodimerization of the IL-2Rβ and γc chains
[5–7]. Both IL-2Rβ and γc are members of the cytokine
receptor superfamily [8]. 
Heterodimerization of IL-2Rβ and γc results in receptor
phosphorylation, transcriptional activation and induction
of cellular kinases (reviewed in [1]). One of the most prox-
imal of these events is the JAK–STAT pathway, in which
receptor-activated Janus kinases (JAKs) promote the tyro-
sine phosphorylation of signal transducers and activators of
transcription (STAT) factors (reviewed in [9–12]). The
IL-2Rβ chain is constitutively associated with JAK1,
whereas γc binds JAK3 [6,13]. Following ligand binding,
JAK1 and JAK3 are activated. This activation is followed
in turn by tyrosine phosphorylation of various STAT
factors, including STAT1, STAT3 and STAT5 [14–20], of
which the primary target appears to be STAT5. There are
two human and murine isoforms of STAT5 (STAT5A and
STAT5B) that are encoded by distinct genetic loci [20–23].
Following phosphorylation, STAT5 dimerizes through
reciprocal phosphotyrosine–SH2 domain interactions; these
dimers subsequently undergo translocation to the nucleus,
where they mediate transcriptional activation. IL-2 stimu-
lates the DNA-binding activity of both STAT5A and
STAT5B [24,25].
In virtually all of the cellular contexts studied to date, JAK
activation is critical for IL-2-mediated proliferation. A
number of IL-2Rβ-chain mutants that fail to activate JAK
kinases also display markedly decreased or undetectable
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proliferative responses to IL-2 [26]. However, JAK1 and
JAK3 may play somewhat disparate roles in the receptor
complex, since certain IL-2Rβ mutants fail to activate
JAK1 detectably yet permit induction of JAK3 kinase
activity and STAT5 induction [27]. A deletion mutant,
IL-2Rβ-H, activates JAK1 and JAK3 but fails to induce
STAT5 dimerization. Cell lines that stably express this
mutant proliferate in response to IL-2, suggesting that
STAT activation is not required for IL-2-mediated cell
proliferation [18]. In contrast, a receptor chain mutant that
permits cell proliferation but fails to activate JAK kinases
has not been identified, suggesting that proliferation and
JAK kinase activation may be interdependent functions in
the context of the IL-2R.
The above evidence, as well as the behavior of other
cytokine receptors, suggests that the JAKs within the 
IL-2R complex may contribute in different ways to
downstream signaling. For instance, in the interferon-
gamma (IFN-γ) system, JAK1 appears to have a critical
role as a molecular scaffold rather than contributing a
crucial enzymatic function [28]. In contrast, the kinase
function of JAK2 is required for all measurable signaling
properties of the IFN-γ receptor. Thus, in some cases,
the JAK may primarily be required for a structural func-
tion in a cytokine receptor complex, whereas in others
JAK catalytic function is strictly necessary for effective
downstream signaling.
The precise mechanism by which JAKs undergo activa-
tion remains unresolved. A common site of positive regu-
lation by phosphorylation is a region between conserved
subdomains VII and VIII of the kinase domain that has
been termed the activation loop (reviewed in [29–31]).
Phosphorylation in this loop may occur on tyrosine, serine
or threonine residues, depending on the substrate speci-
ficity of the kinase. All four recognized members of the
JAK family contain a conserved pair of tyrosines within
this loop. These tyrosines appear to have a regulatory role
in TYK2 and JAK2 [32,33]. 
The present studies were undertaken to determine whether
the analogous tyrosines of JAK1 and JAK3 regulate the
activation of these molecules. Additionally, studies were
performed to determine whether the catalytic function of
these JAKs is required for STAT5 induction following
IL-2 binding to its receptor.
Results
STAT5A is a better substrate for JAK1 than JAK3 in vitro
There is considerable evidence that JAK1 and JAK3 are
required for STAT5A and STAT5B induction following
IL-2 stimulation. To test whether JAK1 and JAK3 can
directly and specifically phosphorylate STAT5A, a recom-
binant substrate composed of the maltose-binding protein
(MBP) fused to the carboxy-terminal 157 amino acids of
STAT5A (MBP–STAT5A) was expressed in bacteria and
purified. The MBP–STAT5A Y694F substrate contains a
single amino-acid substitution at the specific tyrosine that
becomes phosphorylated following cellular stimulation
and is critical for STAT5 dimerization [34]. When the
MBP–STAT5A substrate was incubated with activated
JAK1 in vitro, vigorous tyrosine phosphorylation of this sub-
strate was observed (Figure 1). In contrast, co-incubation of
the MBP–STAT5A substrate with activated JAK3 pro-
duced weak phosphorylation, despite robust autophospho-
rylation of JAK3 itself. Coomassie staining of these protein
gels demonstrated that JAK1 and JAK3 were equivalently
expressed (data not shown). Despite the presence of 20
retained tyrosine residues, the MBP–STAT5A Y694F sub-
strate was not detectably phosphorylated by either JAK1 or
JAK3, suggesting that the kinase reaction does exhibit sub-
strate specificity in vitro. Therefore, both JAK1 and JAK3
can phosphorylate STAT5A to varying degrees on the
physiologically relevant tyrosine in vitro, and the critical
phosphorylation site within STAT5A may be phosphory-
lated more avidly by JAK1 than by JAK3.
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Figure 1
JAK1 and JAK3 are capable of phosphorylating tyrosine 694 of
STAT5A in vitro. JAK1 and JAK3 were immunoprecipitated from 
COS-7 lysates. Immunoprecipitates were split into two equal portions
and incubated with either MBP–STAT5A (lanes 1–3) or
MBP–STAT5A Y694F (lanes 4–6). Phosphoproteins were visualized
by autoradiography. The purified MBP–STAT5A substrates migrate as
doublets; the lower band is presumably a degradation product. The
positions of molecular mass markers (in kDa) are indicated. The arrows
indicate the positions of MBP–STAT5A.
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JAK1 is regulated by phosphorylation of tyrosine residues
within its activation loop
For both JAK1 and JAK3, tyrosine phosphorylation corre-
lates with catalytic activation (reviewed in [10,12]), but
whether these phosphorylation events are essential for
JAK1 and JAK3 activation is unknown. As the activation
loop of JAK1 contains two potential sites of tyrosine
phosphorylation, Y1033 and Y1034 (Figure 2a), one or
both of these residues were mutated to phenylalanine.
These mutants will henceforth be referred to as JAK1FF
to indicate the double tyrosine to phenylalanine mutation,
JAK1FY to refer to the Y1033F mutation, and JAK1YF to
denote the Y1034F mutation. An enzymatically deficient
JAK1 that contains an alanine substitution at the critical
active-site lysine residue was also prepared (K907A).
When transiently expressed in COS-7 cells, all of these
mutants were expressed at levels comparable to those of
the wild-type protein (Figure 2b). 
It has been previously demonstrated that overexpression
of the JAKs in COS-7 or Sf9 cells results in constitu- 
tive activation and concomitant tyrosine phosphorylation
([35,36]; K.D.L., data not shown). To determine the cat-
alytic potential of these JAK1 mutants, each kinase was
co-expressed with STAT5A in COS-7 cells, which results
in ligand-independent STAT5A tyrosine phosphoryla-
tion and the acquisition of DNA-binding activity [24].
Such phosphorylation in this system proved specific,
since co-expression of a JAK with a STAT5A molecule
lacking the critically phosphorylated tyrosine (Y694F) did
not result in STAT5A phosphorylation ([34]; data not
shown). Nuclear extracts were prepared and subjected to
electrophoretic mobility shift assays (EMSA) using a
radiolabeled probe encoding the STAT DNA-binding
site found upstream of the FcγRI gene. Co-expression of
STAT5A with the wild-type JAK1 resulted in a DNA–
protein complex with retarded mobility relative to the
unbound probe that contained STAT5A (Figure 2c, lanes
1,2). In contrast, co-expression of the JAK1K907A mutant
with STAT5A did not yield detectable STAT5A DNA-
binding activity (Figure 2c, lane 3). Similarly, the JAK1FF
mutant failed to activate STAT5A, indicating that one or
both of these tyrosines are critical for kinase function
(Figure 2c, lane 4). The JAK1FY and JAK1YF mutants
clarified that the first tyrosine (Y1033) is required for
kinase activation while the second tyrosine (Y1034) is
dispensable (Figure 2c, lanes 5,6). 
It was also possible in the same system to examine JAK1
phosphorylation, which is thought to be an autocat-
alytic event in the context of overexpression. Expression
of wild-type JAK1 or JAK1YF kinase molecules in 
COS-7 cells resulted in detectable phosphorylation of
tyrosine residues of JAK1 (Figure 2d). Despite expres-
sion levels comparable to those of the wild-type protein,
the JAK1K907A, JAK1FF and JAK1FY mutants failed to
undergo detectable autophosphorylation. Thus, tyrosine
1033 is critical for JAK1 kinase function and may also 
be a site of autophosphorylation.
Activation-loop tyrosines are not absolutely required for
JAK3 catalytic function
We next focused on the two analogous tyrosines within
the activation loop of JAK3, Y975 and Y976 (Figure 2a).
These two tyrosines were mutated to phenylalanine to
create the double mutant, JAK3FF, as well as the two
single mutants, JAK3FY and JAK3YF. All of these
mutants and the kinase-inactive JAK3K851A mutant
were expressed in COS-7 cells at levels comparable to
that of wild-type JAK3 (Figure 3a). When co-expressed
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Figure 2
JAK1 requires activation loop tyrosines for catalytic activation. (a)
Domain structure of JAK1 and JAK3. Residues targeted for
mutagenesis are highlighted in bold. The VAVK sequence is from
subdomain II of the kinase domain. (b) Equivalent expression in COS-7
cells of wild-type and mutant JAK1 proteins was confirmed by
SDS–PAGE followed by immunoblotting with an anti-JAK1 antibody.
(c) To assess the catalytic function of these mutants, each JAK1 was
co-expressed with STAT5A in COS-7 cells. Nuclear extracts were
prepared and subjected to electromobility shift assay (EMSA) with a
radiolabeled FcγRI probe. (d) To determine if the wild-type JAK1 and
JAK1 mutants were tyrosine phosphorylated when expressed in 
COS-7 cells, whole cell lysates (left) or JAK1 immunoprecipitates
(right) were immunoblotted with 4G10. Membranes were stripped and
reprobed with the anti-JAK1 antibody to confirm equivalent loading (for
cell lysates, see (b); for immunoprecipitations, data not shown).
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with STAT5A, wild-type JAK3 strongly activated the
DNA-binding activity of STAT5A (Figure 3b, lane 2). In
contrast, the kinase-deficient JAK3K851A mutant failed to
induce the DNA-binding activity of STAT5A (Figure 3b,
lane 3). Remarkably, the JAK3FF mutant also mediated
STAT5A induction at a level comparable to that of the
wild-type JAK3 (Figure 3b, lane 4). Therefore, in con-
trast to JAK1, the presence of activation-loop tyrosines is
not absolutely critical for the catalytic function of JAK3.
However, the two single tyrosine add-back mutants sug-
gested that the presence of the first tyrosine modestly
influences JAK3 regulation, since JAK3FY failed to phos-
phorylate STAT5A as strongly as JAK3FF in the over-
expression study (Figure 3b, lane 5). Nonetheless, the
JAK3FY mutant itself became phosphorylated on tyrosine
residues when overexpressed in COS-7 cells (Figure 3c), at
levels comparable to those of wild-type JAK3. Together
with the in vitro kinase data (in which JAK3 failed to
phosphorylate STAT5A strongly), this result suggests
that STAT5A may not be the preferred substrate for
JAK3. Consequently, the subtle decrement in function of
JAK3FY may be enhanced upon co-expression with
STAT5A in COS-7 cells. Furthermore, both the JAK3YF
and JAK3FF mutants also became tyrosine phosphorylated
when overexpressed in COS-7 cells (Figure 3c), confirming
that the JAK3FF mutant retained catalytic function despite
the complete absence of the regulatory- loop tyrosines.
Thus, whereas JAK1 is strictly regulated via tyrosines
within the activation loop, the analogous tyrosines do not
play an equivalent role within JAK3. These tyrosines may
nevertheless play some role in regulating catalytic function,
since the JAK3FY mutant does not phosphorylate STAT5A
as strongly as either wild-type JAK3 or JAK3FF, despite a
potent ability to autophosphorylate.
JAK regulation involves intramolecular interactions as well
as the inherent functions of the kinase domain
Because JAK1 and JAK3 are differentially regulated by
activation-loop tyrosines, we next studied whether the
regulation of these kinases was solely an intrinsic prop-
erty of the kinase domain or whether regulation also
involved other domains of the molecule. To address this
question, a panel of JAK1 and JAK3 chimeras was devel-
oped (Figure 4a). All these constructs were expressed at
equivalent protein levels when transfected into COS-7
cells, indicating equal stability (Figure 4b). In co-expres-
sion studies with STAT5A, both of the chimeras with
wild-type kinase domains, namely JAK1/3/3 and JAK3/1/1,
could phosphorylate STAT5A and activate its DNA-
binding activity (Figure 4c). As expected, neither JAK
3/1/1 KA nor JAK 1/3/3 KA, both of which contained catalyt-
ically inactive kinase domains, phosphorylated STAT5A
when co-expressed in COS-7 cells (Figure 4c). This result
again demonstrated the dependence of tyrosine phospho-
rylation of STAT5A on the catalytic activity of the co-
expressed JAK. Interestingly, the JAK3/1/1 FF chimera
continued to phosphorylate STAT5A despite the loss of
tyrosines within the activation loop. Therefore, the amino-
terminal domain of JAK3 can confer regulation upon the
kinase domain of JAK1 independent of the activation-
loop tyrosines since the parental JAK1FF displayed no
detectable kinase activity. In contrast, the fusion of the
amino terminus of JAK1 in the JAK1/3/3 FF chimera did
not detectably affect the preserved activity of the JAK3FF
kinase domain, as measured by the induction of STAT5A
DNA-binding activity.
Whereas both wild-type JAK1/3/3 and JAK1/3/3 FF were
strongly phosphorylated on tyrosine residues when over-
expressed in COS-7 cells, the JAK3/1/1 FF and JAK3/1/1
FY constructs were only weakly tyrosine phosphorylated
despite retaining their catalytic function (Figure 4d). The
kinase-like and kinase domains of JAK3 may contain addi-
tional sites of autophosphorylation that may not be repre-
sented in the equivalent domains of JAK1. Thus, the
regulation of JAKs cannot be assigned exclusively to a
single domain of the kinase but is a function of both the
amino terminus and the kinase domain of the molecule. 
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Figure 3
Activation-loop tyrosines of JAK3 are not strictly required for catalytic
function. Experiments were performed as described in the legend to
Figure 2. (a) Expression of wild-type JAK3 and JAK3 mutants to
confirm comparable levels of expression. Immunoblotting was
performed with an anti-JAK3 antibody. (b) Co-expression of wild-type
JAK3 and JAK3 mutants with STAT5A to assess the catalytic function
of these kinases. EMSA was performed to determine the
phosphorylation state of STAT5A. (c) Assessment of the tyrosine-
phosphorylation state of wild-type JAK3 and mutants in COS-7 cells
by immunoblotting with 4G10. Left panel, whole cell lysates. Right
panel, immunoprecipitations with the anti-JAK3 antibody. Membranes
were stripped and immunoblotted with the anti-JAK3 antibody to
confirm equivalent loading (for cell lysates, see (a); for
immunoprecipitations, data not shown). 
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The amino terminus of JAK1 is critical for the association
between IL-2Rb and JAK1
It remains unclear which domains of JAK1 are responsible
for constitutive association of JAK1 with the IL-2Rβ chain.
For other JAKs, the amino-terminal domain appears to be
the critical determinant of receptor binding [37–40]. To
test this hypothesis for JAK1 and to demonstrate that the
amino terminus of the JAK1/3/3 chimera was appropriately
folded, IL-2Rβ was co-expressed in COS-7 cells with
JAK1, JAK3, or JAK1/3/3. Both JAK1 and JAK1/3/3 were
detectably and specifically co-immunoprecipitated with
IL-2Rβ (Figure 5a), demonstrating that the amino termi-
nus of JAK1 is critical for association with IL-2Rβ. Thus,
the amino terminus of JAK1 confers all of the determi-
nants required for binding to the IL-2Rβ chain and, as its
function is retained, this domain appears to be appropri-
ately folded in the JAK1/3/3 chimera.
IL-2-dependent STAT5 activation is recapitulated by
expression of IL-2Rb, g
c
, JAK1, JAK3 and STAT5A in U4A
To determine the functional JAK requirements for IL-2-
mediated STAT activation, we reconstituted the IL-2R
in U4A cells, a somatic mutant derivative of the 2FTGH
human fibrosarcoma cell line that lacks endogenous
JAK1 [41] and apparently fails to express JAK3. Comple-
mentary DNAs (cDNAs) encoding IL-2Rβ, γc, JAK1,
JAK3 and STAT5A were introduced into the cells by
transient co-transfection. Since STAT5A and STAT5B
appear to be largely interchangeable in the context of IL-
2R signaling [24], for simplicity only the cDNA encoding
STAT5A was used in these studies. Following stimulation
of the cells with IL-2, nuclear extracts were prepared 
and subjected to EMSA with the FcγRI probe. When 
all five cDNAs (IL-2Rβ, γc, JAK1, JAK3 and STAT5A)
were transfected into the U4A cells, STAT5A DNA-bind-
ing activity was undetectable in the absence of ligand
(Figure 6, lane 1). The addition of IL-2 produced a strong
DNA-binding complex (Figure 6, lane 2). Supershift
Research Paper IL-2 signaling and JAK phosphorylation Liu et al. 821
Figure 4
Figure 5
JAK1 and JAK1/3/3 co-immunoprecipitate with the IL-2Rβ chain. (a) Co-
immunoprecipitation experiments. Immunoprecipitations were performed
with the 561 antibody (anti-IL-2Rβ), subjected to SDS–PAGE and then
immunoblotted with the indicated antibodies. (b) Equivalent expression
of JAK1, JAK3 and JAK1/3/3. Cell lysates were subjected to
SDS–PAGE and then immunoblotted with the indicated antibodies.
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JAK1/3/3 and JAK3/1/1 chimeras do not
require activation-loop tyrosines for catalytic
function. (a) Schematics of chimera structure.
(b) JAK1/3/3 and JAK3/1/1 chimeras are
expressed at equivalent levels. JAK1/3/3
proteins are recognized by the anti-JAK3
antibody and JAK3/1/1 proteins are
recognized by the anti-JAK1 antibody. (c)
Assessment of the catalytic function of
JAK1/3/3 and JAK3/1/1 chimeras. The ability
of these kinases to phosphorylate 
co-expressed STAT5A in COS-7 cells was
measured by EMSA. (d) Autophosphorylation
of JAK1/3/3 and JAK3/1/1 in COS-7 cells.
Tyrosine-phosphorylated proteins were
detected by immunoblotting with 4G10.
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analysis with an anti-STAT5 antibody confirmed that
STAT5A was present in this complex (Figure 6, lane 3).
Similar results were obtained with a probe encoding the
STAT-binding site from the interferon-regulatory factor 1
(IRF-1) promoter (data not shown). To determine whether
each of the five cDNAs was required for IL-2-mediated
STAT5A activation, each of the components was sequen-
tially eliminated from the transfection. No combination of
four cDNAs was sufficient to mediate significant IL-2-
induced STAT DNA-binding activity (Figure 6, lanes
4–13). The low but detectable level of STAT5 induction
observed in the absence of transfected IL-2Rβ receptor
chains may be due to a low level of endogenous receptor
chains. Therefore, IL-2Rβ, γc, JAK1, JAK3 and STAT5A
are necessary and sufficient to recapitulate IL-2-inducible
STAT5A activation. 
JAK1 and JAK3 catalytic functions are required for IL-2-
mediated STAT5A activation
The U4A reconstitution system was next used to evaluate
the JAK1 and JAK3 mutants in the context of IL-2-
induced STAT5A activation. For JAK1, only wild-type
JAK1 and the catalytically active JAK1YF mutant permit-
ted full IL-2-induced STAT5A dimerization. In con-
trast, neither the JAK1K907A nor the JAK1FF mutant
reconstituted STAT5A activation (Figure 7a, compare
lanes 2,4,6). However, the JAK1FY mutant, which had no
detectable function in the overexpression system, exhib-
ited a very low but reproducible level of STAT5A induc-
tion in this assay system (Figure 7a, lane 8). These results
demonstrate that STAT5A activation requires intact cat-
alytic function of JAK1 and that the JAK1FY mutant may
retain a small degree of catalytic potential. 
In the case of JAK3, the JAK3K851A mutant failed to
recapitulate IL-2-mediated STAT5 DNA-binding activ-
ity, demonstrating that JAK3 catalytic activity is critical for
STAT5A. In contrast, both JAK3FY and JAK3YF, as well
as JAK3FF, fully supported activation of STAT5A by the
IL-2R (Figure 7b, lanes 6,8,10). All of these mutants thus
retain biologically relevant catalytic function despite the
lack of activation-loop tyrosines. Therefore, these regula-
tory mutants of JAK1 and JAK3 confirm that catalytic
potential of both kinases is critical for IL-2-induced
STAT5A activation.
Discussion
The JAK–STAT pathway was defined through a somatic
genetic approach that demonstrated that the JAKs are
epistatic to the STATs (reviewed in [10–12,28]). There is
less evidence that JAKs directly phosphorylate STATs
during receptor-mediated signaling [36,42]. Immunopre-
cipitates of JAK1 and JAK3 phosphorylated wild-type
MBP–STAT5A but failed detectably to phosphorylate
MBP–STAT5A Y694F, supporting the hypothesis that
JAKs can directly phosphorylate STATs. In addition, JAK1
phosphorylated STAT5A somewhat more efficiently than
did JAK3 in vitro, suggesting that the JAKs may have dif-
ferent substrate specificities. Nonetheless, when overex-
pressed in COS-7 cells, JAK3 activated STAT5A DNA-
binding activity. In this case, the high effective substrate
concentration within the cell may overcome the lower sub-
strate affinity that is physiologically relevant. Notably,
JAK3FY did not phosphorylate STAT5A as effectively as
the wild-type kinase in the COS-7 co-expression system,
although this mutant reconstituted IL-2R function equiva-
lently to wild-type JAK3. These results suggest that the
role of JAK3 in the receptor complex may not be to phos-
phorylate STAT5 directly. Rather, it may normally serve
to phosphorylate the receptor chains, JAK1, or another
unidentified component involved in the initiation of sig-
naling. Therefore, the difference revealed by the in vitro
kinase assay may reflect a subtle but important difference
in substrate specificity that is somewhat obscured in the
overexpression system.
We next pursued the role of activation-loop tyrosines in
JAK1 and JAK3 catalytic activation. The TYK2 Y1054F
Y1055F mutant functions only at very high doses of IFN-γ
[33], and it remains unclear which of these two tyrosines is
critical for kinase activation. As has been shown for JAK2
[32], our studies demonstrate that the first tyrosine within
the activation loop of JAK1 plays the dominant role in
Figure 6
IL-2-induced STAT5A activation is dependent upon co-transfection of
cDNAs encoding IL-2Rα, γc, STAT5A, JAK1 and JAK3. U4A cells were
transfected with the indicated cDNAs. At 48 h post-transfection, cells
were incubated in medium alone (–) or in medium containing 10 nM
recombinant human IL-2 (2) for 10 min at 37°C. Nuclear extracts were
subjected to EMSA. Supershift analysis with the anti-STAT5A antibody
(lane 3) was performed as described in Materials and methods.
Arrows: STAT5A–DNA complex (lower), supershifted STAT5A–DNA
complex (upper).
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catalytic activation. JAK1YF behaved identically to the
wild-type kinase in the assays we have used in this study.
Activation-loop tyrosines may be sites of autophosphory-
lation or transphosphorylation, as the presence of these
tyrosines also correlates with detectable tyrosine phospho-
rylation of JAK1. Alternatively, another kinase may phos-
phorylate the JAKs on these tyrosines, as with Bruton’s
tyrosine kinase (BTK), for which Src kinases initiate BTK
activation by phosphorylating tyrosine 551 within the acti-
vation loop [43]. Furthermore, recent structural studies
suggest that activation-loop phosphorylation may effect
kinase activation by multiple mechanisms. In the insulin
receptor kinase, an activation-loop tyrosine binds to the
active site of the enzyme, thereby blocking substrate and
ATP access [44]. In contrast, in the fibroblast growth factor
receptor, the activation loop blocks the substrate- binding
site, but not the ATP-binding site [45]. Moreover, the criti-
cal activation-loop determinants are not tyrosines but rather
invariant amino acids. A precise understanding of the role of
the activation loop in the regulation of JAK1 will await
further structural characterization of the kinase domain.
In contrast to the other known JAKs, the catalytic activity
of JAK3 was not strictly dependent on the presence of
the activation-loop tyrosines. If phosphorylation of these
tyrosines was essential for kinase activation, mutation of
both tyrosines to phenylalanine would not have permitted
catalytic function. Alternatively, phosphorylation might
create docking sites for signaling intermediates containing
SH2 or phosphotyrosine-binding domains. Ongoing studies
are focused on clarifying the mechanism of JAK3 activation.
Analysis of JAK1–JAK3 chimeras demonstrated that kinase
regulation cannot be mapped to a single domain. A chimeric
molecule in which the amino terminus is derived from
JAK3 and the kinase-like and kinase domains are derived
from JAK1 was constructed in order to determine whether
this chimera behaves like JAK1 or JAK3 with regard to the
role of regulatory loop tyrosines in catalytic activation. The
JAK3/1/1FF chimera, in contrast to JAK1FF, retained sig-
nificant catalytic function. To test whether catalytic regula-
tion is determined solely by the amino terminus of the mol-
ecule, we generated a series of JAK1/3/3 chimeras. The
amino-terminal domain of these molecules appears to be
properly folded, since the JAK1/3/3 chimera associated with
the IL-2Rβ chain when these molecules were co-expressed
in COS-7 cells. However, the JAK1/3/3 FF chimera func-
tioned comparably to its wild-type parent. These findings
suggest that the inherent catalytic function of the kinase
domain plays a role in the regulation of kinase activity,
since the kinase retained its catalytic function in the pres-
ence of the JAK1 amino-terminal domain. Taken together
with the JAK3/1/1 chimera, which demonstrated that the
amino-terminal portion of a JAK could influence its cat-
alytic function, these data suggest that the regulation of
kinase activity involves both interactions with the amino
terminus of the molecule as well as the inherent potential
of the kinase domain itself.
To create an experimental model in which both JAKs could
be replaced in the IL-2R complex, essential components of
the receptor were reconstituted in the somatic mutant
human fibrosarcoma cell line U4A. In contrast to the previ-
ously described COS-7 overexpression system ([25]; K.D.L,
unpublished observations), both JAK1 and JAK3 must be
added to the U4A cellular background to reconstitute IL-2-
inducible STAT5 activation. No mutant form of either
JAK1 or JAK3 lacking catalytic function was capable of sup-
porting signals leading to STAT5A DNA-binding activity
following stimulation with ligand. Therefore, in contrast to
the IFN-γ system [28], it appears that the IL-2R complex
fully requires two catalytically active JAKs for STAT5 acti-
vation. The specific regulation of these two kinases
nonetheless appears to differ at the molecular level.
Conclusions
These studies investigated the potential regulatory role of
conserved tyrosine residues present within the activation
loops of JAK1 and JAK3. These tyrosines are required for
JAK1 but not JAK3 function and therefore are likely to
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Figure 7
The IL-2R requires functional JAK1 and JAK3
for STAT5 activation. (a) U4A cells were
transfected with the JAK1 mutants described
in Figure 2, in combination with IL-2Rβ, γc,
STAT5A and JAK3. WT, wild-type JAK1; KA,
JAK1K907A; FF, JAK1FF ; FY, JAK1FY; and
YF, JAK1YF. Cells were incubated with
medium alone (–) or IL-2 (2) and nuclear
extracts were prepared and subjected to
EMSA. (b) EMSA of nuclear extracts
prepared from U4A cells transfected with the
JAK3 mutants described in Figure 3 along
with IL-2Rβ, γc, STAT5A and JAK1. WT, wild-
type JAK3; KA, JAK3K851A; FF, JAK3FF; FY,
JAK3FY; YF, JAK3YF.
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play fundamentally different roles in the regulation of
activation. Since JAK3 does not require these tyrosines for
catalytic function, ongoing studies are focused on the role
of tyrosine phosphorylation in the regulation of JAK3 acti-
vation. We have also reconstituted functional IL-2R com-
plexes in the U4A cell line, which lacks endogenous JAK1
and JAK3. These studies demonstrated that both JAK1
and JAK3 must be catalytically active in order for IL-2-
induced STAT5 activation to occur. Although these find-
ings highlight the potential importance of JAK1 in the
activation of STAT5, further studies are needed to deter-
mine in more detail the relationships between the IL-2R
chains, JAKs and their substrates.
Materials and methods
Cell lines
The COS-7 cell line was obtained from the American Type Culture Col-
lection. These cells were passaged in Iscove's medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), L-glutamine, and
1% penicillin/streptomycin (P/S). For transient transfection studies,
these cells were passaged in Dulbecco's modified Eagle medium sup-
plemented with 10% FBS, L-glutamine, and 1% P/S. The U4A cell line
was a generous gift from George Stark. Cell culture conditions for this
cell line have been previously described [41].
Reagents and antibodies
The antiphosphotyrosine antibody 4G10 and antibodies specific for
JAK1 and JAK3 were obtained from Upstate Biotechnology. The poly-
clonal rabbit anti-STAT5A antibody was a generous gift from Xiuwen Liu
and Lothar Heninghausen. The anti-Glu antibody coupled to Sepharose
beads was a kind gift of Simon Cook. The cDNAs encoding murine JAK1
and JAK3 were a generous gift of James Ihle. The cDNA encoding
STAT5A was a kind gift of Alice Mui. Recombinant human IL-2 was a gift
of Chiron Corporation. The 561 hybridoma (the anti-IL-2Rβ antibody)
was a kind gift of Paul Sondel. Competent DH5α cells were from Life
Technologies. Pfu polymerase for PCR was obtained from Stratagene
and deoxynucleotides were from Pharmacia.
Constructs and plasmids 
Mutations generated by PCR were verified by DNA sequencing. The
STAT5A Y694F mutant was created by PCR, cloned into pBS-
STAT5A, and then transferred to the pCMV4HA vector. The cDNA
encoding murine JAK1 was subcloned into pCMV4neo [46]. JAK1 was
3′ tagged with the Glu-Glu tag [47,48] by introduction of a PCR
product encoding the epitope hexapeptide (EYMPME, single-letter
amino-acid code) into pJAK1neo. pJAK1FFneo, pJAK1FYneo, and
pJAK1YFneo were generated by PCR. To prepare the JAK1K907A
mutant, a double-stranded oligonucleotide encoding the mutation
was introduced into pJAK1neo. The JAK3 cDNA was subcloned from
pBSmuJAK3 into pCDM8dX and then transferred to pCMV4neo. A
noncoding BamHI fragment was removed to create pJAK3neo. To
create the epitope-tagged JAK3, the 3′ end of JAK3 was subcloned
into pBS to create pBS3′JAK3, and a double-stranded oligonucleotide
encoding the epitope tag was introduced. The JAK3K851A mutant was
generated using a double-stranded oligonucleotide. The JAK3FF
mutant was generated by PCR. The JAK3YF and JAK3FY mutants
were generated with the Mutagene system (BioRad) and oligonu-
cleotides encoding the appropriate mutations. Exchange of comple-
mentary sequences between JAK1 and JAK3 was used to generate the
JAK3/1/1 and JAK1/3/3 chimeras. To create the JAK3/1/1 chimera,
PCR was used to amplify the amino terminus of JAK3 with appropriate
restriction sites and cloned into pJAK1neo. The sequence at the junc-
tion is as follows: FHTIP516 578LKKDI (italic sequences are derived
from JAK3, bold sequences are from JAK1). Mutants were prepared by
subcloning of the amino-terminal fragment of pJAK3/1/1neo into the
appropriate pJAK1neo plasmids. To create the JAK1/3/3 chimera, the
5′ end of JAK3 was cloned into pBS and a unique AflII site was intro-
duced. The 5′ end of JAK1 was subcloned into this construct. This
JAK1/3 fusion was reintroduced into the context of full-length JAK3 (as
well as into the JAK3 mutants). The sequence of the junction is as
follows: DRILK579 514DSLEW.
Fusion protein expression
The MBP–STAT5A fusions were created by cloning a blunted RsrII
site–XbaI fragment of STAT5A that encodes the carboxy-terminal 157
amino acids in frame into the XmnI–XbaI sites of the pMAL-C2 vector
(New England Biolabs). The fusion proteins were produced in DH5α
and purified using amylose resin (New England Biolabs) per the manu-
facturer's instructions. 
Transient transfection methods
COS-7 cells were transiently transfected using Lipofectamine (Life
Technologies) as directed by the manufacturer. The U4A cell line was
transiently transfected by the calcium phosphate method (Life Tech-
nologies) at a density of 2 × 106 per 100 mm plate. 
Electrophoretic mobility shift assays
Nuclear extracts were prepared as described in [49]. Electrophoretic
mobility shift assays were performed with 5 µg nuclear extract from
COS-7 cells or 10 µg extract from U4A cells as described [15,50].
Oligonucleotide probes were radiolabeled using polynucleotide kinase
(Boehringer Mannheim) and γ-[32P]ATP (Amersham) as described [51].
Oligonucleotides and pre-incubation of nuclear extracts with anti-
STAT5 antibodies are as described in [15].
SDS–PAGE and western blotting 
For expression studies, cells were lysed in 1 × SDS–PAGE loading
buffer. Lysates were subjected to SDS–PAGE on 8.75% acrylamide
gels, transferred to Immobilon-P (Millipore) or NitroPure (Micron Sepa-
rations, Inc) and immunoblotted with the indicated antibodies. Chemi-
luminescent detection was performed with the ECL system (Amersham).
To verify equal protein loading, membranes were stripped and reprobed
according to the manufacturer's instructions. 
Immunoprecipitations 
COS-7 cells were lysed in 1% NP-40 (Calbiochem), 20 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10µg ml–1 leupeptin, 10 µg ml–1
aprotinin, and 1 µg ml–1 pepstatin A. The lysates were precleared 3× 30
min (561 antibody) or 2 × 60 min (JAK antibodies). Lysates were incu-
bated with the appropriate antibody (2µg for the 561 antibody, 5 µl for
the anti-JAK1 and JAK3 antibodies) for 1 h, followed by addition of
protein A beads (Boehringer-Mannheim) for 1 h. Beads were washed
three times with lysis buffer and boiled with SDS–PAGE sample buffer.
In vitro kinase assays
Cells were collected in TEN buffer (150 mM NaCl, 40 mM Tris-HCl
pH 7.5, 1 mM EDTA) and lysed in 1% NP-40 lysis buffer. Following
immunoprecipitation with the anti-Glu beads, the beads were washed
twice in lysis buffer and once in kinase buffer (0.5% NP-40, 140 mM
NaCl, 25 mM Hepes pH 7.2, 1 mM MgCl2, 1 mM MnCl2, 2 mM sodium
orthovanadate, 1 mM PMSF, 10 µg ml–1 leupeptin, 10 µg ml–1 apro-
tinin, and 1 µg ml–1 pepstatin A). Kinase reactions were initiated by
adding 40 µl of kinase buffer supplemented with 1–10 mM cold ATP
(Boehringer Mannheim), 10 µCi γ-[32P]ATP (Amersham), and 2–5 µg
substrate. Reactions were incubated at 37°C for 10 min and stopped
by the addition of SDS–PAGE loading buffer. Following SDS–PAGE,
proteins were visualized by Coomassie staining. The stained gel was
subjected to autoradiography to assess phosphorylation.
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